Current evidence-based recommendations on investigating children with global developmental delay

Renuka Mithyantha, Rachel Kneen, Emma McCann, Melissa Gladstone, Renuka Mithyantha, Rachel Kneen, Emma McCann, Melissa Gladstone

Abstract

Introduction: Global developmental delay (GDD) affects 1%-3% of the population of children under 5 years of age, making it one of the most common conditions presenting in paediatric clinics; causes are exogenous, genetic (non-metabolic) or genetic (metabolic). Recent advances in biotechnology and genetic testing mean that the investigations available to perform for children under 5 years are increasing and are more sensitive than previously. This change in availability and type of testing necessitates an update in the recommendations for investigating GDD.

Methods: We conducted a review of the literature from 2006 to 2016 to identify articles with evidence relating to the investigation of developmental delay in children under the age of 5 years. We collated the evidence into first-line and second-line investigations and, where available, on their yield and cost implications.

Results: We have provided up-to-date guidance for first-line and second-line investigations for children with GDD under the age of 5 years. Recent evidence demonstrates that genetic testing for all children with unexplained GDD should be first line, if an exogenous cause is not already established. Our review of the literature demonstrates that all patients, irrespective of severity of GDD, should have investigations for treatable conditions. Evidence demonstrates that the yield for treatable conditions is higher than previously thought and that investigations for these metabolic conditions should be considered as first line. Additional second-line investigations can be led by history, examination and developmental trajectories.

Discussion: We may need to update present recommendations in the UK for investigation of developmental delay. This would include microarray testing as first line and a more thorough approach to investigations for metabolic disorders that can be treated. Clinical assessment remains vital for guiding investigations.

Keywords: genetics; neurodevelopment; neurodisability.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Flow chart for decision making for investigations for global developmental delay in young children.

References

    1. Majnemer A, Shevell MI. Diagnostic yield of the neurologic assessment of the developmentally delayed child. J Pediatr 1995;127:193–9. 10.1016/S0022-3476(95)70294-6
    1. Shevell M, Ashwal S, Donley D, et al. . Practice parameter: evaluation of the child with global developmental delay: report of the quality standards subcommittee of the american academy of neurology and the practice committee of the child neurology society. Neurology 2003;60:367–80. 10.1212/01.WNL.0000031431.81555.16
    1. Shevell MI, Majnemer A, Rosenbaum P, et al. . Etiologic yield of subspecialists' evaluation of young children with global developmental delay. J Pediatr 2000;136:593–8. 10.1067/mpd.2000.104817
    1. Moeschler JB, Shevell M. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics 2014;134:e903–e918. 10.1542/peds.2014-1839
    1. Shonkoff JP, Hauser-Cram P. Early intervention for disabled infants and their families: a quantitative analysis. Pediatrics 1987;80:650–8.
    1. Baird G, McConachie H, Scrutton D. Parents' perceptions of disclosure of the diagnosis of cerebral palsy. Arch Dis Child 2000;83:475–80. 10.1136/adc.83.6.475
    1. Hayeems RZ, Babul-Hirji R, Hoang N, et al. . Parents' experience with pediatric microarray: transferrable lessons in the era of genomic counseling. J Genet Couns 2016;25:298–304. 10.1007/s10897-015-9871-3
    1. McDonald L, Rennie A, Tolmie J, et al. . Investigation of global developmental delay. Arch Dis Child 2006;91:701–5. 10.1136/adc.2005.078147
    1. Silove N, Collins F, Ellaway C. Update on the investigation of children with delayed development. J Paediatr Child Health 2013;49:519–25. 10.1111/jpc.12176
    1. O’Byrne JJ, Lynch SA, Treacy EP, et al. . Unexplained developmental delay/learning disability: guidelines for best practice protocol for first line assessment and genetic/metabolic/radiological investigations. Ir J Med Sci 2016;185:241–8. 10.1007/s11845-015-1284-7
    1. Engbers HM, Berger R, van Hasselt P, et al. . Yield of additional metabolic studies in neurodevelopmental disorders. Ann Neurol 2008;64:212–7. 10.1002/ana.21435
    1. van Karnebeek CD, Scheper FY, Abeling NG, et al. . Etiology of mental retardation in children referred to a tertiary care center: a prospective study. Am J Ment Retard 2005;110:253–67.doi:10.1352/0895-8017(2005)110[253:EOMRIC];2
    1. Wong VC, Chung B. Value of clinical assessment in the diagnostic evaluation of Global Developmental Delay (GDD) using a likelihood ratio model. Brain Dev 2011;33:548–57. 10.1016/j.braindev.2010.09.009
    1. Cleary MA, Green A. Developmental delay: when to suspect and how to investigate for an inborn error of metabolism. Arch Dis Child 2005;90:1128–32. 10.1136/adc.2005.072025
    1. Srour M, Mazer B, Shevell MI. Analysis of clinical features predicting etiologic yield in the assessment of global developmental delay. Pediatrics 2006;118:139–45. 10.1542/peds.2005-2702
    1. Duker AL, Teed LN, Thomas RL, et al. . ’The cost and yield of evaluations for developmental delay/mental retardation'. Dev Med Child Neurol 2008;50:798–9. 10.1111/j.1469-8749.2008.03087.x
    1. Srour M, Shevell M. Genetics and the investigation of developmental delay/intellectual disability. Arch Dis Child 2014;99:386–9. 10.1136/archdischild-2013-304063
    1. Miller DT, Adam MP, Aradhya S, et al. . Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86:749–64. 10.1016/j.ajhg.2010.04.006
    1. Sagoo G, Mohammed S. Array CGH for learning disability - when is it worth it? : PHG Foundation.
    1. Kharbanda M, Tolmie J, Joss S. How to use microarray comparative genomic hybridisation to investigate developmental disorders. Arch Dis Child Educ Pract Ed 2015;100:24–9. 10.1136/archdischild-2014-306022
    1. Lunt P. Testing criteria for fragile X syndrome: report of the outcome from the UKGTN fragile X workshop. London: UK Genetic Testing Network.
    1. Flore LA, Milunsky JM. Updates in the genetic evaluation of the child with global developmental delay or intellectual disability. Semin Pediatr Neurol 2012;19:173–80. 10.1016/j.spen.2012.09.004
    1. Arias A, Corbella M, Fons C, et al. . Creatine transporter deficiency: prevalence among patients with mental retardation and pitfalls in metabolite screening. Clin Biochem 2007;40:1328–31. 10.1016/j.clinbiochem.2007.07.010
    1. van Karnebeek CD, Stockler IS. Evidence-based approach to identify treatable metabolic diseases causing intellectual disability. 2011.
    1. van Karnebeek CD, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab 2012;105:368–81. 10.1016/j.ymgme.2011.11.191
    1. van Karnebeek CD, Shevell M, Zschocke J, et al. . The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource. Mol Genet Metab 2014;111:428–38. 10.1016/j.ymgme.2014.01.011
    1. Galloway P. Best practice guidelines for the biochemical Iivestigation of global developmental delay for Inherited Metabolic Disorders (IMD). 28-1-2013: national metabolic biochemistry network, 2013.
    1. Michelson DJ, Shevell MI, Sherr EH, et al. . Evidence report: genetic and metabolic testing on children with global developmental delay: report of the quality standards subcommittee of the american academy of neurology and the practice committee of the child neurology society. Neurology 2011;77:1629–35. 10.1212/WNL.0b013e3182345896
    1. Sayson B, Popurs MA, Lafek M, et al. . Retrospective analysis supports algorithm as efficient diagnostic approach to treatable intellectual developmental disabilities. Mol Genet Metab 2015;115:1–9. 10.1016/j.ymgme.2015.03.001
    1. Griffiths PD, Batty R, Warren D, et al. . The use of MR imaging and spectroscopy of the brain in children investigated for developmental delay: what is the most appropriate imaging strategy? Eur Radiol 2011;21:1820–30. 10.1007/s00330-011-2144-0
    1. Verbruggen KT, Meiners LC, Sijens PE, et al. . Magnetic resonance imaging and proton magnetic resonance spectroscopy of the brain in the diagnostic evaluation of developmental delay. Eur J Paediatr Neurol 2009;13:181–90. 10.1016/j.ejpn.2008.04.014
    1. Verbruggen KT, Maurits NM, Meiners LC, et al. . Quantitative multivoxel proton spectroscopy of the brain in developmental delay. J Magn Reson Imaging 2009;30:716–21. 10.1002/jmri.21909
    1. Martin E, Keller M, Ritter S, et al. . Contribution of proton magnetic resonance spectroscopy to the evaluation of children with unexplained developmental delay. Pediatr Res 2005;58:754–60. 10.1203/
    1. Verity C, Winstone AM, Stellitano L, et al. . The epidemiology of progressive intellectual and neurological deterioration in childhood. Arch Dis Child 2010;95:361–4. 10.1136/adc.2009.173419
    1. Davidson N, Skull S, Chaney G, et al. . Comprehensive health assessment for newly arrived refugee children in Australia. J Paediatr Child Health 2004;40:562–8. 10.1111/j.1440-1754.2004.00465.x
    1. Centers for Disease Control and Prevention (CDC). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment--United States, 2003. MMWR Morb Mortal Wkly Rep 2004;53:57–9.
    1. Great Ormond Street Hospial for Children NHS Foundation Trust,North East Thames Regional Genetics Service. Pricing, 2014.
    1. Community Children’s Health Partnership. Investigations for developmental delay: blood tests costs (2014) and what results could indicate? 2014.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever